• Explore /
  • Poster
  • / Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.

Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.

Abstract Poster

Authors

null

Margaret K. Callahan

Department of Medicine at Memorial Sloan-Kettering Cancer Center, New York, NY

Margaret K. Callahan , Johanna C. Bendell , Emily Chan , Michael Morse , Rathi Narayana Pillai , Petri Bono , Dirk Jaeger , T.R. Jeffry Evans , Ian Chau , Emiliano Calvo , Dung T. Le , Patrick Alexander Ott , Matthew Hiram Taylor , Padmanee Sharma , Scott Joseph Antonia , Brian Sharkey , Olaf Christensen , Asim Amin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics - Immunotherapy

Track

Developmental Therapeutics

Sub Track

Immunotherapy and Biologic Therapy

Clinical Trial Registration Number

NCT01928394

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3114)

DOI

10.1200/jco.2014.32.15_suppl.tps3114

Abstract #

TPS3114

Poster Bd #

179B

Abstract Disclosures

Similar Posters

First Author: Erlinda Maria Gordon

Poster

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab, and nivolumab as first-line treatment of advanced soft tissue sarcoma (STS).

Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab, and nivolumab as first-line treatment of advanced soft tissue sarcoma (STS).

First Author: Erlinda Maria Gordon

First Author: Yelena Yuriy Janjigian

First Author: Dung T. Le